The Russian Direct Investment Fund (
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V. Sputnik Light demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered.
The data was obtained from Russians vaccinated with a single injection, having not received the second one for any reason during the mass vaccination program between December 5, 2020 and April 15, 2021. An efficacy level of near 80% is higher than that of many two-dose vaccines.
In February 2021, Kazakhstan approved the two-dose
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
Sputnik V is already successfully used in Kazakhstan to prevent the spread of coronavirus. Registration of Sputnik Light will help provide the country with another highly effective and safe vaccine against coronavirus. Single-dose Sputnik Light vaccine will enable authorities to speed up the vaccination of the population and accelerate the creation of herd immunity.